Quantitative mass spectrometry has become an indispensable tool in proteomic studies. Numerous methods are available and can be applied to approach different issues. In most studies these issues include the quantitative comparison of different cell states, the identifi cation of specifi c interaction partners or determining degrees of posttranslational modifi cation. In this chapter we describe a SILAC-based quantifi cation in order to analyze dynamic protein changes during the assembly of the human spliceosome on a pre-mRNA in vitro. We provide protocols for assembly of spliceosomes on pre-mRNA (including generation of pre-mRNAs and preparation of nuclear extracts), quantitative mass spectrometry (SILAC labeling, sample preparation), and data analysis to generate timelines for the dynamic protein assembly.
Introduction
Eukaryotic pre-mRNAs consist of protein-coding sequences (exons) and noncoding sequences (introns). The introns are defi ned by very short, conserved sequences at the 5′ and 3′ splice sites (i.e., the exon/intron and intron/exon junctions) as well as the branch-point site, which contains a conserved adenosine (branch-point adenosine) and in most cases a polypyrimidine tract (Y n ; Fig. 1a ) .
During pre-mRNA splicing, the introns are excised and the exons are ligated to yield mature mRNA. This proceeds by two consecutive transesterifi cation reactions (Fig. 1b ) : First, the 2′ hydroxyl group of the branch-point adenosine attacks the phosphodiester bond at the 5′ splice site (5′ss) resulting in a phosphodiester bond between the branch-point adenosine and the fi rst nucleotide of the intron. In the second step of splicing, the free 3′ hydroxyl group of exon1 attacks the phosphodiester bond of the 3′ splice site (3′ss); in this way, exon 1 and exon 2 become ligated and the intron is released in the form of a lariat (Fig. 1b ) [ 1 -5 ].
The Spliceosome

Eukaryotic Pre-mRNAs
The process of eukaryotic pre-mRNA splicing is highly dynamic and is catalyzed by the spliceosome-a multi-megadalton machine that assembles from the so-called U snRNPs (uridine-rich small nuclear ribonucleoprotein particles) as well as non-snRNP proteins. There are fi ve spliceosomal U snRNPs: the U1, U2, U4, U5, and U6 snRNPs and also the U4/U6 di-snRNP and the U4/U6.U5 tri-snRNP. All U snRNPs consist of a specifi c uridine-rich RNA (U snRNA) and a particle-specifi c set of proteins (for review see [ 6 ] ).
Common to all U snRNPs (except U6) are seven Sm proteins (E, F, G, D1, D2, D3, and B/B′), which form a ring-shaped heptamer and bind the U snRNA at the Sm site via a Sm motif [ 7 -9 ] . The U6 snRNA instead associates with a group of related proteins, called Sm-like proteins (LSm2-LSm8). They also form a heptameric ring and bind the U6 snRNA at the 3′ end [ 10 , 11 ] .
In addition, every U snRNP contains a set of particle specifi c proteins: The U1 snRNP contains the U1-A, U1-70K, and U-1C proteins. Of these, U1-C is important for splicing activity, as it directly contacts the pre-mRNA near the 5′ss ( see Fig. 1a ) stabilizing snRNA-pre-mRNA interactions [ 12 , 13 ] . The 12S U2 snRNP contains in addition to the Sm proteins two additional proteins U2-A′ and U2-B″, and the splicing active U2 snRNP, was found two contain two further heteromeric splicing factors-SF3a and The splicing reaction follows two transesterifi cation steps, after which the spliced mRNA (Exon1-Exon2) and the intron-lariat are released SF3b, composed of three and fi ve proteins, respectively [ 14 -16 ] . SF3a and SF3b proteins contact the pre-mRNA near the branch point site ( see Fig. 1a ) and are essential for the spliceosomal assembly [ 17 , 18 ] . The U5 snRNP contains eight U5 specifi c proteins with an apparent molecular weight of 15, 40, 52, 100, 102, 116, 200, and 220 kDa [ 19 ] ; most of these are involved in structural rearrangements in the fi rst step of splicing (reviewed by [ 20 ] . The U5 snRNP is recruited to the spliceosome after tri-snRNP formation with U4/U6 di-snRNP comprising U4 and U6 snRNAs, Sm and LSm proteins, and fi ve U4/U6 specifi c proteins (Fig. 2 ) . The thus formed U4/U6.U5 tri-snRNP contains all U4/U6 and U5 proteins (except U5-52K) and three additional proteins (110K, 65K, and 27K proteins), which are required for integration into the spliceosome [ 21 ] . In addition to the snRNP-specifi c proteins, additional non-snRNP protein components play important roles in pre-mRNA splicing. The hPrp19/CDC5L complex is one of them. It consists of seven proteins (CDC5L, Hsp70, CTNNBL1, PRL1, hPrp19, AD-002, and SPF27; [ 22 , 23 ] ) and associates with additional related proteins with the U5 snRNP to form the remodeled 35S U5 [ 23 ] during activation of the spliceosome (Fig. 2 ) . It is suggested to play a crucial role in the assembly of a catalytically active spliceosome, presumably by stabilizing the RNA interaction network in the catalytic core [ 22 ] .
Several other splicing factors belong to the DExD/H-box protein family: These proteins are able to rearrange RNP and RNA-RNA interactions and are therefore required for structural rearrangements. Some belong to U snRNP specifi c proteins (e.g., U5-220K, U5-100K, see above), whereas others are non-snRNP specifi c (e.g., hPrp5, UAP56, hPrp2). Furthermore, other proteins that have been found to be specifi c for the different spliceosomal transition states. For instance, Prp16, Prp17, Prp18, Prp22, and Slu7 (reviewed by [ 24 ] ) have been reported to bind the spliceosome after the fi rst step of splicing to function at the second step of splicing-these are so-called second step splicing factors.
Complete pre-mRNA splicing in higher eukaryotes hence requires several processes: (1) the ordered assembly of the U snRNPs on the pre-mRNA in concert with the recruitment of additional non-snRNP splicing factors, (2) the partial dissociation of these factors upon rearrangement of the gross structure of the spliceosome and the accompanying disruption and formation of protein-protein, RNA-RNA, and protein-RNA binding, (3) the completion of the two transesterifi cation steps, and (4) the release of the mature mRNA generated (for detailed review see [ 25 ] ).
The spliceosome assembles on the pre-mRNA in a stepwise manner, passing through a series of functional intermediates. The various states are outlined for the human spliceosome in Fig. 2 . In the fi rst assembly step, the U1 snRNP binds to the 5′ss of the 1.1. 3 Assembly of the Spliceosome pre-mRNA, forming the E ("early") complex [ 12 , 26 ] . The recruitment of U2 snRNP leads then to formation of the A complex, which is also called the pre-spliceosome [ 27 , 28 ] . Upon integration of the U4/U6.U5 tri-snRNP and additional splicing factors, called B specifi c proteins, the pre-catalytic spliceosome (B complex) is developed [ 29 ] . Structural RNA and protein rearrangements within the B complex induced by RNA helicases Brr2 (U5-200K) and Snu114 (U5-116K) cause the dissociation of U1 and U4 snRNPs. Dissociation of U1 and U4 together with U4/U6 specifi c proteins and remodeling of U5 initiated by the binding of the hPrp19/CDC5L complex generate the activated spliceosome (B*), Fig. 2 The stepwise assembly of the spliceosome during pre-mRNA splicing. First, U1 snRNP binds to the 5′ss forming the E complex followed by binding of U2 snRNP (A complex formation). Recruitment of the pre-assembled tri-snRNP (U4/U6.U5) leads to formation of the pre-catalytic B complex. Upon structural rearrangements U1 and U4 snRNPs dissociate and incorporation of the hPrp19/ CDC5L complex leads to remodeling of U5 generating the activated B complex. The fi rst step of splicing occurs in this intermediate assembly yielding the C complex, in which the second step of splicing is carried out. The generated mRNA and the post-spliceosomal complex are released and the splicing factors are reconstituted. In addition to the protein complex hPrp19/CDC5L, numerous non-snRNP specifi c proteins, not shown here, join and leave the spliceosome at various points during the cycle in which the fi rst catalytic step of splicing occurs [ 30 , 31 ] . The complex that forms during this process is the catalytically active C complex, which goes on to perform the second step of splicing for which the second step splicing factors (see above) are required [ 32 ] . The fi nal steps are the release of the mature mRNA product, dissociation of the post-spliceosomal intron complex, and recycling of the splicing factors (Fig. 2 ).
So far, only few studies have applied quantitative mass spectrometry combined with metabolic labeling using stable isotopes to describe dynamic protein changes in ribonucleoprotein complexes. In a fi rst study, the SILAC strategy was applied to analyze the proteome of the nucleolus from differentially labeled cells after different durations of treatment [ 33 ] . The time-dependent composition profi les of protein subunits from RNA polymerase I, snRNPs and ribosomes were recorded [ 33 ] . In a similar manner, the assembly kinetics of the 30S ribosomal subunit of Escherichia coli have been studied by quantitative pulse-chase MS (PC/QMS). N ratio in their proteins was used to reveal the binding kinetics [ 34 ] . In this chapter we describe the quantitative analysis of the dynamic protein changes that occur during premRNA splicing by using stable isotope labeling and subsequent mass spectrometry.
The distinct assembly states of the human spliceosome (i.e., A, B, B*, and C complexes, see above) in vitro have been analyzed in previous studies and compared in a semi-quantitative manner to determine differences in their protein compositions [ 27 , 29 , 30 , 32 , 35 ] . However, this approach only monitors the quantitative changes of the protein composition during the transition of one purifi ed state of the spliceosomes to another. Yet no description of the dynamic protein changes that occur during assembly of proteins pre-mRNA splicing in a time dependent manner has been applied. We therefore used SILAC quantifi cation to monitor the protein assembly on a pre-mRNA in a time-dependent manner.
We used MS2-tagged PM5 pre-mRNA, which in previous studies had been successfully applied to purify catalytically active spliceosomes [ 32 ] , and a splicing-inactive variant of this premRNA, which was generated by deletion of the 5′ss. A direct comparison was made between the assembled proteins on the splicing-active and on the splicing-inactive pre-mRNA at different time points during pre-mRNA splicing (Fig. 3 ) .
For this purpose, we prepared HeLa nuclear extracts from differentially labeled HeLa cells (light and heavy SILAC cells; Table 1 ).
Analyzing Dynamic Protein Changes by Quantitative Mass Spectrometry
Protein Assembly and Dynamics of the Human Spliceosome
Pre-mRNA splicing was then performed using the two premRNAs (splicing-active and splicing-inactive) and the two SILAC nuclear extracts (Fig. 3 ) . The splicing reaction was stopped at different time points and the assembled complexes were affi nitypurifi ed by using the MS2-tag that was present on both pre-mRNAs. The samples to be compared were pooled in the same amounts and the proteins were separated by gel electrophoresis. The proteins were digested in-gel and the peptides generated were analyzed by LC-online MS/MS. Peptide and protein ratios were obtained by using the MaxQuant software [ 36 ] . Protein ratios were normalized by calculating a normalization factor for each time point from background protein ratios, as these is supposed to be present in equimolar amounts on both pre-mRNAs. The protein assembly of distinct spliceosomal protein groups was displayed by plotting their average normalized protein ratios against time.
Fig. 3
Experimental setup to monitor protein dynamics during pre-mRNA splicing. SILAC nuclear extracts were prepared from differentially labeled HeLa cells (light and heavy; the additional masses arising from the isotopically labeled lysine and arginine are indicated on the left ). Splicing reactions were assembled on PM5 and 5′ss deleted PM5 pre-mRNA using light and heavy nuclear extracts, respectively. Assembled complexes from the same time point but assembled on the different pre-mRNAs were pooled in equal amounts In this chapter, we show some examples of the kinetics of the protein assembly on the two pre-mRNAs analyzed for spliceosomal protein groups that are affected by deletion of the 5′ss. We compared the assembly dynamics for the U1, U2 snRNPs and the hPrp19/CDC5L complex proteins, all of which are components of different spliceosomal intermediate states (see above). Our results demonstrate that, differences in the protein assembly on the two pre-mRNAs were identifi ed by direct comparison (Fig. 4 ) . The U1 snRNP is specifi c for the pre-catalytic spliceosomal complexes (Fig. 2 ) and, at early time points, its proteins are more abundant on the splicing-active pre-mRNA than on the splicing-inactive pre-mRNA as obtained from their high SILAC protein ratios between zero and 5 min (Fig. 4 ) . For the U2 snRNP proteins, Fig. 4 Protein assembly timelines for spliceosomal protein groups. Assembly on the splicing-active (heavy SILAC nuclear extract) and splicing-inactive (light SILAC nuclear extract) PM5 pre-mRNA was directly compared. Assembly timelines for U1 snRNP, U2 snRNP, and hPrp19/CDC5L specifi c proteins are shown. Differences in the assembly on the two pre-mRNAs are observed. The U1 snRNP proteins are more abundant on the splicing-active PM5 pre-mRNA than on the splicing-inactive pre-mRNA during the fi rst time points of pre-mRNA splicing. Their SILAC protein ratios decrease after approximately 5 min clearly demonstrating that they dissociate from the pre-mRNA. The U2 snRNP proteins instead do not show any differences in their assembly on the two pre-mRNAs. They bind to the branch-point site of the pre-mRNA and are thus not affected by the 5′ss deletion. They show constant protein ratios of approximately 1:1 over the whole time frame, meaning that they are present to the same extent on both premRNAs. The hPrp19/CDC5L complex proteins do not show differences in their assembly on the two pre-mRNAs for the fi rst time points represented by their protein ratios of 1:1. After 5 min of splicing their protein ratios increase significantly showing that they associate with the spliceosome after 5 min. This is in agreement with their role in the assembly of the activated spliceosome. Increased protein ratios of members of the hPrp19/CDC5L also reveal that they are more abundant on the splicing-active pre-mRNA indicating that catalytically active spliceosomes are not formed on the splicing-inactive pre-mRNAs which are present in all intermediate states (Fig. 2 ) , no differences were observed between the two pre-mRNAs (Fig. 4 ) .
Interestingly, the hPrp19/CDC5L complex, which the spliceosome incorporates during its activation (see above and Fig. 2 ), assembles at later time points only on the splicing-active premRNA; the SILAC protein ratios increased signifi cantly after 2 min of incubation for this group of proteins. Thus, our quantitative MS results demonstrate that the different protein groups indeed show different assembly kinetics, and they also show which proteins are affected by the deletion on the 5′ss. The timelines generated for the assembly of whole spliceosomal protein groups during premRNA splicing thus contribute substantially toward gaining an understanding of this dynamic process.
Materials
HeLa S3 cells (wt).
2. DMEM, high glucose, w/o arginine, w/o lysine.
Dialyzed fetal bovine serum (FBS).
4. 100× penicillin-streptomycin. 
2.5 L fermenter (bioreactor).
9. See also Notes 1 -3 and Table 1 . 1. Phosphate-buffered saline (PBS): 130 mM NaCl, 0.2 mM K-PO 4 , ice-cold.
2. MC buffer: 10 mM HEPES-KOH pH 7.6, 10 mM KOAc, 0.5 mM Mg(OAc) 2 , ice-cold.
0.25 M dithioerythritol (DTE).
4. EDTA-free protease inhibitor cocktail (Roche). 9. Dialysis tubing (MWCO 6,000-8,000 Da).
10. See also Note 5 .
SILAC Labeling of HeLa Cells
Preparation of SILAC HeLa Nuclear Extracts
4. 50 mM maltose dissolved in 20 mM HEPES-KOH pH 7.6, 1.5 mM MgCl 2 , 150 mM NaCl. 5. See also Note 11 .
1. Ultrapure water.
Acetonitrile (ACN).
3. 100 mM ammonium bicarbonate (NH 4 CO 3 ), pH 8.0.
4. 10 mM DTT in 100 mM NH 4 CO 3 .
5. 55 mM iodoacetamide (IAA) in 100 mM NH 4 CO 3 .
6. 5 % (v/v) formic acid (FA).
7. Trypsin (sequencing grade, 0.1 μg/μl). 10. Gel loader pipette tips.
Thermomixer (Eppendorf).
12. Vacuum centrifuge.
13. See also Notes 12 and 13 .
1 % (v/v) FA (loading buffer).
2. See Note 14 .
1. Computer system (Intel Pentium III/800 MHz or higher, 2 GB RAM minimum).
2. MaxQuant software package.
3. GProx software platform.
4.
See also Notes 15 and 16 .
Methods
1. Prepare custom-made DMEM containing the following ingredients ( see Table 1 for combinations of light and heavy L -arginine and L -lysine to obtain duplex SILAC medium): (a) 500 ml DMEM w/o arginine, w/o lysine.
(b) 50 ml dialyzed FBS. 
Quantifi cation and LC-MS Analysis
Data Analysis
SILAC Labeling of HeLa Cells
(c) 5 ml of 100× penicillin-streptomycin.
(d) 5.55 ml of 50 mg/l l-arginine.
(e) 5.55 ml of 50 mg/l l-lysine.
2. Grow HeLa S3 cells in small volumes for at least six passages and then expand to 2.0 L in spinner fl asks (0.5-1.0 × 10 6 cells/ ml). GpppG cap, 20 mM MgCl 2 , 10 mM DTT, 0.1 μg/ml BSA, 1 U/μl RNasin, 0.1 μg/μl DNA template, and 2 U/μl SP6 RNA polymerase. Adjust the volume to 50 ( 32 P-labeled premRNA) or 150 μl (non-labeled pre-mRNA) with RNAse-free water.
2. Incubate for approx. 4 h at 40 °C.
3. Digest the DNA template using 1 U of RQ1 DNase/μg template and incubate for 20 min at 37 °C.
4. Purify RNA transcripts by gel purifi cation using 5 % polyacrylamide gels containing 8 M urea.
Preparation of SILAC HeLa Nuclear Extracts
In Vitro
Transcription of Pre-mRNA 5. Visualize unlabeled RNA by UV-shadowing (254 nm) and 32 P-αUTP-labeled RNA by exposure of an X-ray fi lm.
6. Excise bands from the gel.
7. Extract RNA by incubation with RNA extraction buffer overnight.
8. Purify extracted RNA further by Phenol-Chloroform-Isoamyl alcohol PCI extraction and ethanol precipitation (see below).
9. Resuspend the purifi ed RNA in RNase-free water.
10. See also Notes 6 , 7 , 17 , and 18 .
PCI extraction:
1. Mix the sample with 1 volume of PCI and 1 μl of 10 μg/μl glycogen.
2. Vigorously agitate on a vortex (15 min).
3. Separate aqueous and organic phases by centrifugation for 5 min at 13,000 rpm at room temperature.
4. Transfer the aqueous RNA containing phase (upper phase) to a new tube.
5. Add 1 volume of chloroform.
6. Vigorously agitate on a vortex (15 min).
7. Separate aqueous and organic phases by centrifugation for 5 min at 13,000 rpm at room temperature.
8. Transfer the aqueous phase to a new tube and precipitate RNA with ethanol.
Ethanol precipitation:
1. Add 3 volumes of ice-cold 100 % ethanol and 1/10 volumes of 3 M NaOAc, pH 5.3.
2. Incubate at −20 °C for at least 2 h. 6. Remove the supernatant and dry the protein pellet in a vacuum centrifuge.
To perform in vitro splicing and subsequently purify assembled protein-RNA complexes, use m 7 G(5′)ppp(5′)G-capped and MS2-tagged pre-mRNA. In our laboratory, we use a mixture of 32 P-labeled (radioactive) and non-labeled pre-mRNA, i.e., the non-labeled pre-mRNA is spiked with a small amount of radioactive 32 P-labeled pre-mRNA to allow for determination of the concentration. The amount of pre-mRNA and, thus the molar amounts of assembled protein complexes can then be determined by using 11. Dry the gel pieces in a vacuum centrifuge.
Spliceosome Assembly
12. Rehydrate gel pieces on ice with buffer 1.
13. Cover the gel pieces with buffer 2 and carry out the tryptic digestion overnight at 37 °C.
Here, we used the protein ratios of ribosomal proteins which have been found to be present in equal amounts within the different SILAC nuclear extracts.
Clustering of proteins into protein groups can help with the interpretation of the results and is thus an important step during data analysis. In this study, we used GProx for clustering of protein groups. Please refer to protocols provided [ 39 ] . See also Note 16 .
Notes
1. DMEM, FBS, penicillin-streptomycin, and heavy-labeled amino acids are available from different commercial sources in different purity grades.
2. Dissolve amino acids in DMEM and if necessary adjust the pH of the solution by using fi ltered sodium hydroxide solution.
3. As heavy-labeled amino acids are in most cases high-priced, the concentration of lysine and arginine can be reduced compared with normal DMEM. However, the concentration of both amino acids should be adjusted to ensure normal cell growth. The differently labeled cells should in all three casesi.e., light, medium, and heavy cells-be the same to ensure comparability of the cells (nuclear extracts).
4. PMSF is not very soluble in water and is usually dissolved in isopropanol or ethanol. PMSF should be added freshly, below the liquid surface, to avoid precipitation.
5. DTT, DTE and PMSF solutions should be prepared freshly and added before use.
6. Depending on the promoter, each DNA template requires the use of the appropriate RNA polymerase (e.g., SP6 or T7). This protocol describes the use of SP6 polymerase. When a different polymerase is used, the protocol may need to be adjusted.
7. When working with RNA, the use of RNase-free water is highly recommended to avoid RNA hydrolysis. 11. In our laboratory, the NuPAGE gel system has been found to be well-suited for subsequent MS analysis. In principle, any other gel system can be applied to separate the purifi ed protein complexes.
Clustering of Protein Groups
12. For all buffers and solutions, p.a. grade water and solvents should be used.
13. All buffers for in-gel digestion of proteins and extraction of peptides should be prepared freshly before use.
14. Since every laboratory has its own individual setup for LC-MS/ MS, we do not provide a specifi c protocol for this. However, it is worth mentioning that the MaxQuant software [ 36 ] , which has been proven to be well suited for the analysis of SILAC experiments, is only compatible with data acquired on highresolution mass spectrometers (i.e., LTQ-Orbitraps, Exactive and Q-Exactive, and FT-ICR; Thermo Fisher Scientifi c).
15. The MaxQuant software package is freely available ( www. maxquant.org ). Visit the Web site for additional information and support.
16. The software GProx is freely available (http://gprox.sourceforge.net/). Visit the Web site for additional information and support.
17. Addition of 32 P-αUTP will generate radioactively labeled premRNA. The incorporation of 32 P-αUTP will be random. The specifi c activity of the labeled pre-mRNA can be calculated from the mixing ratio of UTP to 32 P-αUTP, the number of uridines within the pre-mRNA and the radioactivity of the 32 P-αUTP.
18. For further information, please see standard molecular biology protocols.
19. In theory, any other software can be used to analyze the raw data on the assembly kinetics of protein(-RNA) complexes. However, the MaxQuant software package is well-suited to the analysis of the large SILAC datasets that are generated when protein dynamics are analyzed. In addition, it can be applied fully automated and provides additional tools, e.g., for statistical analysis of the data obtained.
20. It is highly recommended that one performs an initial experiment pooling the differentially labeled nuclear extracts in a 1:1 ratio. All proteins should be present in equal amounts and should not be upregulated or downregulated in the different extracts. Background proteins that deviate from the overall 1:1 protein ratios should not be selected for normalization of the data.
